Thrombosis and Coagulopathy in COVID-19

Since December 2019, an outbreak of coronavirus disease 2019 (COVID-19) which initially occurred in the city of Wuhan, located in China's Hubei province, spread around the world and on March 11, 2020, the World Health Organization declared the new Coronavirus disease 2019 (COVID-19) as a pandem...

Full description

Saved in:
Bibliographic Details
Published in:Current problems in cardiology 2021-03, Vol.46 (3), p.100742-100742, Article 100742
Main Authors: Gómez-Mesa, Juan Esteban, Galindo-Coral, Stephania, Montes, Maria Claudia, Muñoz Martin, Andrés J.
Format: Article
Language:English
Subjects:
Blood Coagulation Disorders - epidemiology
Blood Coagulation Disorders - etiology
COVID-19 - complications
COVID-19 - epidemiology
Global Health
Humans
Incidence
Pandemics
SARS-CoV-2
Thrombosis - epidemiology
Thrombosis - etiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Since December 2019, an outbreak of coronavirus disease 2019 (COVID-19) which initially occurred in the city of Wuhan, located in China's Hubei province, spread around the world and on March 11, 2020, the World Health Organization declared the new Coronavirus disease 2019 (COVID-19) as a pandemic. The presence of comorbidities (eg, cardiovascular disease, obesity), Sepsis Induced Coagulopathy score >4, elevation of D-dimer (>6 times the normal value), C-reactive protein, troponins and other disseminated intravascular coagulation markers; is associated to a worse prognosis in hospitalized patients with severe COVD-19, reaching a hospital mortality of 42%. Initial anticoagulant treatment with low molecular weight heparin has been shown to reduce mortality by 48% at 7 days and 37% at 28 days and achieve a significant improvement in the arterial oxygen pressure/inspired fraction of O2 (PaO2/FiO2) by mitigating the formation of microthrombi and associated pulmonary coagulopathy.
ISSN:0146-2806
1535-6280
DOI:10.1016/j.cpcardiol.2020.100742